U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07691645) titled 'Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome' on June 29.
Brief Summary: Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases. Under the current targeted and immunotherapy-based treatment approaches, the overall survival of patients with advanced HCC has improved significantly compared to targeted therapy alone. However, there are still limitations in therapeutic effectiveness. In addition to the tumor burden, liver reserve function is associated with the prognosis of HCC. Cirrhosis, tumor burden, and anti-tu...